HansynPharma

Hansoh Pharmaceutical Group is a China-based innovation-driven pharmaceutical company focused on oncology, anti-infectives, central nervous system disorders, metabolic disease, and autoimmune disease. The company markets multiple innovative medicines in China, including Ameile for EGFR-mutant non-small cell lung cancer, Saint Luolai for chronic kidney disease anemia, and Xinyue for rare autoimmune neurologic diseases. Hansoh combines internal drug discovery, clinical development, manufacturing, and commercialization, and has built technology capabilities in small molecules, antibodies, bispecifics, ADCs, and siRNA. Its pipeline includes more than 40 innovative drug candidates across more than 70 ongoing clinical studies. The company is publicly listed in Hong Kong and operates major R&D and manufacturing sites in Lianyungang, Changzhou, Shanghai, and Maryland.